» Articles » PMID: 34451918

Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects

Abstract

Major depressive disorder (MDD) is a complex and common disorder, with many factors involved in its onset and development. The clinical management of this condition is frequently based on the use of some pharmacological antidepressant agents, together with psychotherapy and other alternatives in most severe cases. However, an important percentage of depressed patients fail to respond to the use of conventional therapies. This has created the urgency of finding novel approaches to help in the clinical management of those individuals. Nutraceuticals are natural compounds contained in food with proven benefits either in health promotion or disease prevention and therapy. A growing interest and economical sources are being placed in the development and understanding of multiple nutraceutical products. Here, we summarize some of the most relevant nutraceutical agents evaluated in preclinical and clinical models of depression. In addition, we will also explore less frequent but interest nutraceutical products which are starting to be tested, also evaluating future roads to cover in order to maximize the benefits of nutraceuticals in MDD.

Citing Articles

Effect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.

Siddique A, Khokhar M, Waheed A, Naeem U, Aziz S BMC Pharmacol Toxicol. 2025; 26(1):14.

PMID: 39844190 PMC: 11752948. DOI: 10.1186/s40360-025-00846-x.


Understanding immune system dysfunction and its context in mood disorders: psychoneuroimmunoendocrinology and clinical interventions.

Ortega M, Fraile-Martinez O, Garcia-Montero C, Diaz-Pedrero R, Lopez-Gonzalez L, Monserrat J Mil Med Res. 2024; 11(1):80.

PMID: 39681901 PMC: 11650850. DOI: 10.1186/s40779-024-00577-w.


The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.

Wu S, Yang K, Liu W, Malau I, Zailani H, Chang C Nutrients. 2024; 16(21).

PMID: 39519521 PMC: 11547719. DOI: 10.3390/nu16213688.


Harnessing the Anti-Inflammatory Properties of Polyphenols in the Treatment of Inflammatory Bowel Disease.

Boaru D, Fraile-Martinez O, De Leon-Oliva D, Garcia-Montero C, De Castro-Martinez P, Miranda-Gonzalez A Int J Biol Sci. 2024; 20(14):5608-5672.

PMID: 39494333 PMC: 11528451. DOI: 10.7150/ijbs.98107.


Autophagy in Its (Proper) Context: Molecular Basis, Biological Relevance, Pharmacological Modulation, and Lifestyle Medicine.

Ortega M, Fraile-Martinez O, De Leon-Oliva D, Boaru D, Lopez-Gonzalez L, Garcia-Montero C Int J Biol Sci. 2024; 20(7):2532-2554.

PMID: 38725847 PMC: 11077378. DOI: 10.7150/ijbs.95122.


References
1.
Lopez-Cruz L, Salamone J, Correa M . Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression. Front Pharmacol. 2018; 9:526. PMC: 5992708. DOI: 10.3389/fphar.2018.00526. View

2.
Mann J, Peselow E, Snyderman S, Gershon S . D-phenylalanine in endogenous depression. Am J Psychiatry. 1980; 137(12):1611-2. DOI: 10.1176/ajp.137.12.1611. View

3.
Zou L, Liu W, Liu C, Xiao H, McClements D . Utilizing food matrix effects to enhance nutraceutical bioavailability: increase of curcumin bioaccessibility using excipient emulsions. J Agric Food Chem. 2015; 63(7):2052-62. DOI: 10.1021/jf506149f. View

4.
Martone G . Enhancement of recovery from mental illness with l-methylfolate supplementation. Perspect Psychiatr Care. 2017; 54(2):331-334. DOI: 10.1111/ppc.12227. View

5.
Saccarello A, Montarsolo P, Massardo I, Picciotto R, Pedemonte A, Castagnaro R . Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. Prim Care Companion CNS Disord. 2020; 22(4). DOI: 10.4088/PCC.19m02578. View